#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Non-Hodgkin's lymphoma Transitional cell carcinoma Neonatal asphyxia Squamous cell carcinoma of head and neck Asthma Pulmonary alveolar haemorrhage Adenocarcinoma pancreas Cholangiocarcinoma Anal squamous cell carcinoma Testicular leiomyosarcoma Thalassaemia Antiphospholipid syndrome Neuromyelitis optica spectrum disorder Ovarian epithelial cancer Pelizaeus-Merzbacher disease More trials…

    Learn about Rare Diseases

    Netherton’s syndrome Uterine leiomyosarcoma – Diagnostics Testicular leiomyosarcoma – Treatment Paroxysmal nocturnal haemoglobinuria – Trials in Disease Glycogen storage disease type II – Treatment Mantle cell lymphoma stage IV – Treatment Activated PI3 kinase delta syndrome – Trials in Disease Haemophilia A with anti factor VIII – Treatment Ewing’s sarcoma recurrent – Trials in Disease Ehlers-Danlos syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Icosapent Ethyl MZE829 ALXN1920 GSK5458514 STREPTOCOCCUS VIRIDANS Enzalutamide BMS-986470 Tasimelteon Vatiquinone Rezvilutamide Cpft Trifluoroacetate Quinidine Sulfate Relugolix Gen1055 Clenbuterol Hydrochloride SKB410 F125/10 Dabigatran Duvakitug Lidocaine More therapies…

    Learn about Your Condition

    Lip and/or oral cavity cancer Vaginal cancer Thromboangiitis obliterans Tubulointerstitial nephritis Uterine leiomyoma Lymphocytic lymphoma Familial hypertriglyceridaemia Relapsing multiple sclerosis Habitual abortion Castleman's disease Malignant mast cell neoplasm Periarthritis Ligament sprain Mite allergy Ureteric cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Klinički bolnički centar Zagreb (University Hospital…

Klinički bolnički centar Zagreb (University Hospital Center Zagreb)

Vinogradska Cesta 29, Zagreb, Zagreb, 10000, Croatia

Want to learn more about this study or check if you can participate? Contact us.

  • Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Nivolumab
    • Sunitinib
    Bulgaria Croatia Czechia Denmark Finland France +8

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Camizestrant
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Belgium Croatia France Germany Greece Hungary +4

  • Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Rocatinlimab
    Croatia Czechia Germany Greece Hungary Italy +6

  • Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Anakinra
    • Acasunlimab
    • Betamethasone Sodium Phosphate
    Austria Belgium Bulgaria Croatia Estonia France +9

  • Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Eftilagimod Alfa
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Croatia Germany Greece +9

  • Comparison of two doses of cabozantinib (60 mg vs 140 mg) in patients with progressive metastatic medullary thyroid cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Medullary thyroid cancer
    Investigated Drugs:
    • Cabozantinib
    Croatia Hungary Poland Romania

  • Study Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Pembrolizumab
    Croatia Greece Lithuania Poland Romania Spain

  • Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated Diseases:
    • Primary progressive multiple sclerosis
    Investigated Drugs:
    • Tolebrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +13

  • Study on Long-term Effects of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Secukinumab
    Austria Belgium Bulgaria Croatia Czechia Greece +8
Previous Page
1 2 3 4 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!